| | No DVT/PE at 30 | No DVT/PE at 30 DVT/PE at 30 days | | P-value |
|-----------------------------|-------------------|---------------------------------------|-------------------|---------|
| | days | days (N=14) (N=344) | (N=344) | |
| | (N=330) | | | |
| Age | | · · · · · · · · · · · · · · · · · · · | | 0.1073 |
| N (Missing) | 330 (0) | 14 (0) | 344 (0) | |
| Mean (SD) | 55.5 (12.86) | 60.0 (10.37) | 55.7 (12.79) | |
| Median (IQR) | 56.8 (46.7, 64.8) | 64.4 (54.6, 67.1) | 57.1 (47.7, 64.8) | |
| Range | 20.8, 86.0 | 31.7, 69.8 | 20.8, 86.0 | |
| G ender , n (%) | | | | 0.3348 |
| Male | 137 (41.5%) | 4 (28.6%) | 141 (41.0%) | |
| Female | 193 (58.5%) | 10 (71.4%) | 203 (59.0%) | |
| | 195 (500 %) | 10 (/11//0) | 203 (39.070) | |
| Body Mass Index (kg/m) | | | | 0.3273 |
| N (Missing) | 330 (0) | 14 (0) | 344 (0) | |
| Mean (SD) | 33.1 (6.59) | 31.5 (5.39) | 33.1 (6.55) | |
| Median (IQR) | 33.1 (28.7, 37.1) | 31.9 (27.1, 34.2) | 33.0 (28.7, 37.0) | |
| Range | 19.3, 84.7 | 21.5, 42.2 | 19.3, 84.7 | |
| | | | | |
| Smoking Status, n (%) | | | | 0.7201 |
| No | 327 (99.1%) | 14 (100.0%) | 341 (99.1%) | |
| Current | 3 (0.9%) | 0 (0.0%) | 3 (0.9%) | |
| | | | | |
| Diabetes, n (%) | | | | 0.9095 |
| No | 255 (77.3%) | 11 (78.6%) | 266 (77.3%) | |
| Yes | 75 (22.7%) | 3 (21.4%) | 78 (22.7%) | |
| | | | | |
| Iypertension , n (%) | | | | 0.7458 |
| No | 156 (47.3%) | 6 (42.9%) | 162 (47.1%) | |

Supplemental Digital Content 1: Patient Characteristics

| | No DVT/PE at 30 DVT/PE at 30 days | | Total | P-value |
|---------------------------------------|-----------------------------------|-------------|-------------|---------------------|
| | days | (N=14) | (N=344) | |
| | (N=330) | | | |
| Yes | 174 (52.7%) | 8 (57.1%) | 182 (52.9%) | |
| Chronic Kidney Disease , n (%) | | | | 0.4376 ² |
| No | 282 (85.5%) | 13 (92.9%) | 295 (85.8%) | |
| Yes | 48 (14.5%) | 1 (7.1%) | 49 (14.2%) | |
| | | × , | | |
| Chronic Liver Disease, n (%) | | | | 0.5555 ² |
| No | 322 (97.6%) | 14 (100.0%) | 336 (97.7%) | |
| Yes | 8 (2.4%) | 0 (0.0%) | 8 (2.3%) | |
| | | | | |
| Immunosuppression, n (%) | | | | 0.0443 ² |
| No | 279 (84.5%) | 9 (64.3%) | 288 (83.7%) | |
| Yes | 51 (15.5%) | 5 (35.7%) | 56 (16.3%) | |
| | | | | |
| Hypercoagulable Disorder or History | | | | 0.8642 ² |
| of DVT/PE, n (%) | | | | |
| No | 288 (87.3%) | 12 (85.7%) | 300 (87.2%) | |
| Yes | 42 (12.7%) | 2 (14.3%) | 44 (12.8%) | |
| | | | | 0.40042 |
| History of Malignancy, n (%) | | | | 0.4231 ² |
| No | 318 (96.4%) | 13 (92.9%) | 331 (96.2%) | |
| Yes | 12 (3.6%) | 1 (7.1%) | 13 (3.8%) | |
| COPD , n (%) | | | | 0.9443 ² |
| No | 308 (93.3%) | 13 (92.9%) | 321 (93.3%) | |
| Yes | 22 (6.7%) | 1 (7.1%) | 23 (6.7%) | |
| | | | | |

| | No DVT/PE at 30 DVT/PE at 30 days | | Total | P-value |
|------------------------------------|-----------------------------------|-------------|-------------|---------|
| | days (N=330) | (N=14) | (N=344) | |
| | | | | |
| No | 329 (99.7%) | 14 (100.0%) | 343 (99.7%) | |
| Yes | 1 (0.3%) | 0 (0.0%) | 1 (0.3%) | |
| | | | | |
| nti-coagulation medications, n (%) | | | | 0.9201 |
| No | 304 (92.1%) | 13 (92.9%) | 317 (92.2%) | |
| Yes | 26 (7.9%) | 1 (7.1%) | 27 (7.8%) | |
| | | | | 0.000 |
| Anti-coagulation medications held | | | | >0.999 |
| for operation, n (%) | | | | |
| No | 2 (7.7%) | 0 (0%) | 2 (7.4%) | |
| Yes | 24 (92.3%) | 1 (100%) | 25 (92.6%) | |
| | | | | |
| Anti-platelet medications, n (%) | | | | 0.7816 |
| No | 269 (81.5%) | 11 (78.6%) | 280 (81.4%) | |
| Yes | 61 (18.5%) | 3 (21.4%) | 64 (18.6%) | |
| Anti-platelet medications held for | | | | 0.7328 |
| - | | | | 0.7520 |
| operation, n (%) | | | | |
| No | 15 (%) | 1 (%) | 16 (%) | |
| Yes | 46 (%) | 2 (%) | 48 (%) | |

Kruskal-Wallis p-value; ²Chi-Square p-value; IQR: Interquartile Range; COPD: Chronic Obstructive pulmonary Disease